Skip to content

Impact of Continuous Glucose Monitoring and Education Intervention on Glycemic Control and Behavioral Changes in Pre-Diabetic Adolescents

A Pilot Study Evaluating the Impact of Continuous Glucose Monitoring and Education Intervention on Glycemic Control and Behavioral Changes in Pre-Diabetic Adolescents

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07569185
Acronym
PreDiA-CGM
Enrollment
25
Registered
2026-05-06
Start date
2026-06-01
Completion date
2027-07-30
Last updated
2026-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre Diabetes

Brief summary

Prediabetes is a condition wherein blood sugar levels are elevated but not sufficiently high enough to diagnose type 2 diabetes mellitus (T2D). Prediabetes is a critical risk factor for the development of T2D in pediatric populations. This progression can occur over a short period of time, limiting the efficacy and impact of existing interventions and recommendations targeting this population. There is growing evidence on the use of continuous glucose monitors (CGMs) in adult prediabetic populations to prevent the development of T2D, though this intervention has not been thoroughly investigated in pediatric populations. The investigators are proposing a pilot study of 25 prediabetic adolescents enrolled in a 20-week study. For the initial 10 weeks of the study, the participants will go without CGMs and undergo clinically recommended education on their condition as standard of care. In the 10 weeks following, participants will be given a CGM to wear and instructions on its use. Surveys will be issued to all participants over the entirety of the study to follow behaviors surrounding food and physical activity.

Interventions

DEVICEFitBit and continuous glucose monitoring

The purpose of this pilot study is to evaluate the effectiveness of CGMs in assisting prediabetic adolescents to make appropriate lifestyle changes aimed at preventing the development of T2D. The investigators hypothesize that the use of CGMs over 10 weeks will result in beneficial lifestyle changes, relative to a period without CGM. The investigators will evaluate beneficial lifestyle changes by following eating habits, physical activity levels, and biometric measurements

Sponsors

University of Arizona
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
13 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* • At least 13 years of age * No older than 17 years of age (up to 18th birthday) * Access to a smart-device compatible with a continuous glucose monitor application and wearable biosensor * Diagnosed prediabetes, defined as any of the following: * Fasting plasma glucose of 100- 125 mg/dL * 2-hour glucose level on oral glucose tolerance test (OGTT):140-199 mg/dL * HbA1c 5.7%-6.4%

Exclusion criteria

* • Previous diagnosis of Prader Willi Syndrome * Previous diagnosis of hypothalamic obesity * Previous diagnosis of intellectual disability * Previous or planned bariatric surgery * Current use of medication is known to impact weight * Previous diagnosis of diabetes mellitus * Hemoglobin A1c \>6.5% * Non-English speaking

Design outcomes

Primary

MeasureTime frameDescription
Behavioral Changes as measured by questionnaires20 weeksParticipants will complete a standardized questionnaire assessing dietary intake and physical activity every two weeks throughout the study period. Responses will be recorded using Likert-scale measures. Questionnaire results will be compared across study phases, including before and after continuous glucose monitor (CGM) use, to evaluate changes over time.

Secondary

MeasureTime frameDescription
Physical ActivityFrom enrollment to the end of the study at 20 weeksWe will track physical activity as steps measured by the FitBit.
Height, weight and BMIFrom enrollment to the end of the study at 20 weeksWe will measure height (m), weight (kg) and BMI (kg/m2)

Contacts

CONTACTSunil Sinha, MD
sunil.sinha@bannerhealth.com5206865585

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 7, 2026